Related Experiment Video

Updated: May 31, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Sorafenib for the management of advanced renal cell carcinoma

Bernard Escudier1

  • 1Institut Gustave Roussy, 39 Rue Camille Desmoulins, Villejuif 94805, France. escudier@igr.fr

Expert Review of Anticancer Therapy
|June 29, 2011
PubMed

Insights

Sorafenib (Nexavar®) offers significant clinical benefit for advanced renal cell carcinoma (RCC). This review examines its evidence, impact, and future role in RCC targeted therapy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Sorafenib (Nexavar®) marked a new era in targeted therapy for advanced renal cell carcinoma (RCC).
  • It was the first oral multikinase inhibitor approved for RCC treatment.
  • The Phase III TARGET trial demonstrated its significant clinical benefit.

Purpose of the Study:

  • To review the clinical evidence supporting sorafenib use in RCC.
  • To examine sorafenib's impact on clinical practice.
  • To explore the future role of sorafenib in RCC treatment.

Main Methods:

  • Review of clinical evidence for sorafenib in RCC.
  • Analysis of subpopulations from clinical trials.
  • Examination of sorafenib's impact on clinical practice.

Main Results:

  • Sorafenib demonstrated significant clinical benefit in advanced RCC.
  • Evidence supports its use across various patient subpopulations.
  • Sorafenib has impacted current RCC treatment paradigms.

Conclusions:

  • Sorafenib remains a key targeted therapy for advanced RCC.
  • Understanding its role is crucial with emerging targeted agents.
  • Further evaluation of sorafenib's long-term impact and future applications is warranted.

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Concept Videos

Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...